Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Evelo Biosciences, Inc. - Common Stock (NQ:EVLO)

N/A UNCHANGED
Last Price Updated: 4:00 PM EST, Dec 11, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Evelo Biosciences, Inc. - Common Stock

Evelo Biosciences Announces Top-Line Results From its Phase 2 Clinical Study with EDP2939 in Moderate Psoriasis
From Evelo Biosciences, Inc.
Via GlobeNewswire
Evelo Biosciences Announces Second Quarter Financial Results and Recent Business Highlights
From Evelo Biosciences, Inc.
Via GlobeNewswire
Evelo Biosciences Inc. (NASDAQ: EVLO) Leading the Way in Friday Trading Based on Percentage Gain
Via Investor Brand Network
Exposures COVID-19
Evelo Biosciences Inc. (NASDAQ: EVLO) Near the Top of Equities by Percentage Gain on 7/18
Via Investor Brand Network
Exposures COVID-19
Evelo Biosciences Closes $25.5 Million Private Placement
From Evelo Biosciences, Inc.
Via GlobeNewswire
Evelo Biosciences Announces $25.5 Million Private Placement
From Evelo Biosciences, Inc.
Via GlobeNewswire
Evelo Biosciences Announces Reverse Stock Split Effective
From Evelo Biosciences, Inc.
Via GlobeNewswire
Evelo Biosciences Provides Clinical Updates
From Evelo Biosciences, Inc.
Via GlobeNewswire
Evelo Biosciences Announces Fourth Quarter and Full Year 2022 Financial Results and Business Highlights
From Evelo Biosciences, Inc.
Via GlobeNewswire
Evelo Biosciences to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, March 16, 2023
From Evelo Biosciences, Inc.
Via GlobeNewswire
Evelo Biosciences to Participate in the Cowen 43rd Annual Health Care Conference
From Evelo Biosciences, Inc.
Via GlobeNewswire
Evelo Biosciences Reports that EDP2939, its First Oral Extracellular Vesicle Product Candidate, Commenced Dosing in a Phase 2 Psoriasis Trial
From Evelo Biosciences, Inc.
Via GlobeNewswire
Evelo Biosciences Provides Clinical and Business Updates
From Evelo Biosciences, Inc.
Via GlobeNewswire
Evelo Biosciences Announces $45 Million Loan Agreement with Horizon Technology Finance Corporation to Refinance Existing Debt
From Evelo Biosciences, Inc.
Via GlobeNewswire
Evelo Biosciences Announces Publication of Scientific Basis for SINTAX Medicines in Frontiers in Immunology
From Evelo Biosciences, Inc.
Via GlobeNewswire
Evelo Biosciences Reports Third Quarter 2022 Financial Results and Business Highlights
From Evelo Biosciences, Inc.
Via GlobeNewswire
Evelo Biosciences to Present at the 2022 Jefferies London Healthcare Conference
From Evelo Biosciences, Inc.
Via GlobeNewswire
Global Multiple Sclerosis Drugs Market Expected to Reach $41.99 Billion in 2028
Palm Beach, FL –– February 3, 2022 – FinancialNewsMedia.com News Commentary – Multiple Sclerosis (MS) is an immune-mediated disease of the central nervous system. It is characterized by demyelination,... 
Via FinancialNewsMedia
Exposures COVID-19
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.